Family offices ramp up deals in June with bets on biotech and pharma
Key Points
- After a slow spring, investment firms of the ultra-rich made 60 direct investments in June, according to Fintrx.
- Family offices flocked to biotech and health-care firms such as Antheia, seeking to make an impact and returns at the same time.
- Antheia founder Christina Smolke told CNBC’s Inside Wealth family offices’ patient capital makes them a good fit for investing in scientific breakthroughs.
Read More: Family offices ramp up deals in June with bets on biotech and pharma